Research programme: GPCR modulators - cancer therapies - Heptares Therapeutics

Drug Profile

Research programme: GPCR modulators - cancer therapies - Heptares Therapeutics

Alternative Names: Adenosine A2A modulators; CXCR-4 modulators

Latest Information Update: 25 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Heptares Therapeutics
  • Developer AstraZeneca; Heptares Therapeutics
  • Class Small molecules
  • Mechanism of Action Adenosine A2A receptor antagonists; Chemokine receptor antagonists; G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 25 May 2016 Preclinical trials in Cancer in United Kingdom (PO) before May 2016
  • 23 Feb 2015 Heptares Therapeutics has been acquired by Sosei
  • 15 Dec 2014 Heptares Therapeutics has patent protection for StaR™ (stabilised receptor) technology platform in USA, Europe, China, Japan and Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top